Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs
Earlier this month, Dyne Therapeutics Inc. (NASDAQ:DYN) announced important updates for its DMD and DM1 programs.
Dyne Therapeutics Inc. (DYN)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 5,172,000 | $101,164,320 | +46% | 0.15% |
| 2. | Orbis Investment Management William B. Gray | 4,801,928 | $93,925,712 | 0.39% | |
| 3. | Siren L.L.C. Raymond Debbane | 3,502,941 | $68,517,526 | -26% | 2.04% |
| 4. | Perceptive Advisors Joseph Edelman | 3,478,944 | $68,048,145 | +544% | 1.21% |
| 5. | Armistice Capital Steven Boyd | 3,249,708 | $63,564,288 | +7% | 0.76% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.35 | 2,000 | $38,700.00 | 13,500 | 2026-03-11 | Filing | |
| $9.11 | 100,000 | $911,000.00 | 242,179 | 2025-07-14 | Filing | |
| $33.09 | 7,200 | $238,248.00 | 8,000 | 2024-09-04 | Filing | |
| $32.57 | 800 | $26,056.00 | 800 | 2024-09-04 | Filing | |
| $33.09 | 7,200 | $238,248.00 | 8,000 | 2024-09-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.52 | 129,672 | $2,530,562.05 | 4,644,386 | 2026-03-11 | Filing | |
| $19.80 | 281,858 | $5,580,816.59 | 4,774,058 | 2026-03-10 | Filing | |
| $19.33 | 219,758 | $4,246,823.35 | 5,055,916 | 2026-03-10 | Filing | |
| $18.21 | 9,482 | $172,687.13 | 5,275,674 | 2026-03-10 | Filing | |
| $17.72 | 177,690 | $3,148,986.64 | 5,285,156 | 2026-03-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,887,722 | $271,603,659 | 0.12% | |
| 2. | 11,215,565 | $219,376,451 | 0% | |
| 3. | 11,190,838 | $218,892,793 | 0% | |
| 4. | 9,130,465 | $178,591,895 | 20.64% | |
| 5. | 6,692,745 | $130,910,092 | 0% |
News See All
5 Best Day Trading Stocks to Buy Now
Investment bank Barclays discussed Hims & Hers Health, Inc. (NYSE:HIMS)'s shares on March 11th. It raised the share price target to $29 from $25 and kept an Overweight rating on the stock.
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade
In a market report, Jefferies reiterated its “buy” issuance for Dyne Therapeutics Inc. (NASDAQ:DYN), alongside a $50 price target.
10 Stocks Investors Are Watching: WiPro, USAR, NIO, and More
Ten stocks soared higher on Tuesday, bucking a lackluster performance in the broader market, as investors took path from a flurry of positive developments including analyst ratings and earnings, among...
Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 13 hot stocks to buy with the highest upside potential.
13 Hot Stocks to Buy with the Highest Upside Potential
On average, equities are expected continue to deliver positive results in 2026, this time with greater breadth across sectors, styles, and regions, compared to the other periods of the recent bull market...
Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry
As of the February 12 closing, Dyne Therapeutics (NASDAQ:DYN) held a strongly bullish consensus view. Of the 9 analysts covering the stock, 7 assigned Buy ratings and 2 issued Hold ratings.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (NASDAQ:DYN) is among the 14 best booming stocks to buy right now, with returns of over 23% in the last three months.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Hedge Fund Resource Center